1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B69F33BEF69A2A0A00258BA2002A0F6C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/building-more-effective-medical-affairs-product-launch-teams-metabolic-diseases-segment
18
19
20172.69.58.49
21
22
23527255.sherryhk.tech
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Launch Optimization

Building More Effective Medical Affairs Product Launch Teams: Metabolic Diseases Segment

ID: POP-390


Features:

12 Info Graphics

32 Data Graphics

650+ Metrics

18 Narratives


Pages: 56


Published: 2024


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Given the chronic nature of metabolic diseases, Medical Affairs teams play a critical role in shaping product launch strategies that extend beyond clinical efficacy to focus on patient outcomes, adherence, and real-world effectiveness. Acting as the bridge between R&D, commercial teams, healthcare professionals (HCPs), and patients, Medical Affairs ensures that launch strategies meet the needs of all stakeholders, addressing both clinical and quality-of-life considerations.

Best Practices, LLC conducted this research to probe the expanding role of Medical Affairs in metabolic product launches. This report explores how Medical Affairs teams can drive successful outcomes through evolving responsibilities, enhanced cross-functional alignment, effective evidence dissemination, and strategic resourcing. Our research also highlights critical success factors, challenges, and best practices specific to the metabolic product success, providing actionable insights for Medical Affairs teams aiming to deliver high effectiveness and impact in support of launch.

Industries Profiled:
Pharmaceutical; Consulting; Biopharmaceutical; Communications; Consumer Products; Biotech; Health Care; Medical Device


Companies Profiled:
AstraZeneca; BIAL; Boehringer Ingelheim; Cipla; EMD Serono; Eurofarma; MEDiSTRAVA; Matinas BioPharma; Merck KGaA; NexGen Healthcare Communications; Novartis; Pfizer; Pixacore; Sandoz; Takeda Pharmaceuticals; Terumo BCT: Terumo Blood and Cell Technologies

Study Snapshot

Best Practices, LLC engaged 21 Medical leaders from 16 leading life sciences companies in this benchmarking research study. Medical Directors and upper management executives represent nearly four-fifths of the leaders who shared data and insights on Medical launch activities in this study.

Key topics covered in this report include:

  • Medical Leadership Roles and Launch Activity Effectiveness in Metabolic Diseases Segment
  • Ensuring Cross-functional Alignment and Collaboration in Metabolic Disease Product Launches
  • Medical Launch Evolution in Metabolic Diseases Segment
  • Metabolic Disease Launch Activities Timeline, Performance Tracking, and Resourcing
  • Critical Success Factors and Major Pitfalls for Medical Affairs During Metabolic Disease Product Launches
  • Digital Launch Implementation and Impact in Metabolic Diseases
  • Launch Tool Deployment for Metabolic Disease Products

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Internal Group Collaboration: Medical collaborates early and often with cross-functional launch teams (89%) through clearly defined roles, responsibilities, and expectations (68%) to ensure successful metabolic product launches.
  • Launch Tool Deployment: Metabolic diseases segment participants typically kick off digital activities one phase later than when they should ideally start, according to their own standards. The widest gap occurs in actual medical information engagement time vs. ideal.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive SummaryPg. 4
II.
Section I: Launch Excellence and Medical’s Role & Activity EffectivenessPg. 6-12
III.
Section II: Ensuring Cross-functional Alignment and CollaborationPg. 13-15
IV.
Section III: Adopting to Ongoing Changes in Medical LandscapePg. 16-20
V.
Section IV: Launch Timeline, Preparedness Metrics, and ResourcingPg. 21-26
VI.
Section V: Critical Success Factors and Major PitfallsPg. 27-32
VII.
Section VI: Digital Influence on Launch Processes and Launch Tool DeploymentPg. 33-41
VIII.
Section VII: Participant DemographicsPg. 42-43
IX.
Section VIII: Detailed Benchmark Study DataPg. 44-55
X.
Section IX: About Best Practices, LLCPg. 56

    List of Charts & Exhibits

    I. Launch Excellence and Medical’s Role & Activity Effectiveness

    • Medical launch excellence framework
    • Medical Affairs’ role in metabolic product launches
    • Medical leadership roles in metabolic product launches
    • Medical Affairs’ effectiveness in metabolic product launch activities
    • Most effective launch activities for Medical Affairs in metabolic diseases segment
    • Improvement opportunities for Medical Affairs around metabolic product launch activities

    II. Ensuring Cross-functional Alignment and Collaboration

    • Medical Affairs’ work with internal colleagues to ensure successful metabolic product launches
    • Role of Medical Affairs group in cross-functional metabolic product launch teams

    III. Adopting to Ongoing Changes in Medical Landscape

    • Change fronts for Medical launch evolution
    • Medical Affairs’ launch evolution around digital data dissemination and communication
    • Medical Affairs’ launch evolution around medical education
    • Medical Affairs’ launch evolution around organizational support

    IV. Launch Timeline, Preparedness Metrics and Resourcing

    • Medical Affairs’ metabolic product launch activities timeline
    • Total annual Medical Affairs launch investment in U.S. dollars and number of FTEs for metabolic products during each of the years in launch phase
    • Launch dashboard and information used with the dashboard for metabolic products
    • Percentage of total Medical Affairs launch investment allocated to each of the listed Medical Affairs activities in metabolic products
    • Percentage of total Medical Affairs launch FTEs allocated to each of the listed Medical Affairs activities in metabolic products

    V. Critical Success Factors and Major Pitfalls

    • Critical success factors for Medical Affairs in metabolic product launches
    • Areas where advanced team planning is key for metabolic product launches
    • Six critical areas for successful Medical Affairs launch readiness in metabolic diseases segment
    • Major pitfalls for Medical Affairs during metabolic product launches
    • Six major challenge areas for Medical Affairs during metabolic product launches

    VI. Digital Influence on Launch Processes and Launch Tool Deployment

    • Post-pandemic digital technology utilization in Medical Affairs during metabolic product launches
    • Impact of digital technologies on current and future metabolic product launch processes
    • Digital launch tool deployment and impact
    • Impact of top three digital activities that Medical leads in metabolic diseases segment
    • Impact of digital activities and programs used to support a successful metabolic product launch
    • Top digital tools that can bring success to Medical Affairs product launch activities
    • Fast-growing digital tools that are impacting Medicals’ launch strategy
    • Example of a valuable digital tool that supports launch activities

    VII. Participant Demographics

    • Geographic responsibility of benchmark partners

    VIII. Detailed Benchmark Study Data

    • Role served by Medical Affairs in metabolic product launches
    • Medical Affairs’ launch role effectiveness in metabolic diseases segment
    • Role served by Medical Affairs in planning, research, and education activities in metabolic diseases segment
    • Role served by Medical Affairs in data dissemination and organizational support activities in metabolic diseases segment
    • Role served by Medical Affairs in research activities in metabolic diseases segment
    • Role served by Medical Affairs in education and data dissemination support activities in metabolic diseases segment
    • Role served by Medical Affairs in organizational support activities in metabolic diseases segment
    • Medical Affairs launch activity involvement timeline - Evidence generation and field-based medical activities in metabolic diseases segment
    • Medical Affairs launch activity involvement timeline - Medical information and medical regulatory activities in metabolic diseases segment
    • Medical Affairs launch activity involvement timeline - HEOR activities and medical / scientific communications in metabolic diseases segment
    • Medical Affairs launch activity involvement timeline - Independent medical education and external engagement activities in metabolic diseases segment